US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aardvark Therapeutics

5.09

-0.1700-3.23%

Post-market: 5.100.0100+0.20%19:24 EDT

Volume:266.13K

Turnover:1.35M

Market Cap:110.44M

PE:-2.27

High:5.37

Open:5.30

Low:4.83

Close:5.26

52wk High:17.94

52wk Low:4.74

Shares:21.70M

Float Shares:5.89M

Volume Ratio:0.56

T/O Rate:4.52%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2430

EPS(LYR):-0.7400

ROE:-48.06%

ROA:-30.81%

PB:0.90

PE(LYR):-6.88

Loading ...

Overview Company News Filings

Aardvark Therapeutics Pauses Trial After Finding Safety Issue

BUZZ-Aardvark Therapeutics falls after pausing late-stage rare disease trial

Aardvark Therapeutics down 54% to $5.70 after pausing Phase 3 HERO trial

Aardvark Therapeutics voluntarily pauses Phase 3 HERO trial

Aardvark Therapeutics pauses late-stage trial testing rare disease treatment

Aardvark Therapeutics: Decision Based on Reversible Cardiac Observations at Above Target Therapeutic Doses Found

THOMSON REUTERS

Aardvark Therapeutics: Hero & Open-Label Open-Label Extension Trials Pause Based on Reversible Cardiac Observations Above Target Doses

THOMSON REUTERS

Aardvark Therapeutics pauses Phase 3 HERO trial of ARD-101 in Prader-Willi syndrome

Aardvark Therapeutics Inc trading halted, news pending

Aardvark Therapeutics Announces Voluntary Pause of Phase 3 Hero Trial in Prader-Willi Syndrome

THOMSON REUTERS

Aardvark Therapeutics Inc - Pause Due to Cardiac Observations at Above Target Doses

THOMSON REUTERS

Aardvark Therapeutics Inc - Topline Data Announcement Delayed, Guidance Expected in Q2 2026

THOMSON REUTERS

NASDAQ TRADE HALT HALT NEWS PENDING AT 04:02 PM

BRIEF-Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aardvark Therapeutics Grants Stock Options to New Employees

BRIEF-Aardvark Therapeutics Announces Establishment Of New U.S. Subsidiary

Aardvark Therapeutics Launches Ardia Subsidiary for Dermatology Pipeline Expansion

Aardvark Therapeutics Appoints Derrick C. Li as Chief Business Officer and Expands Nelson Sun's Role

Bryan Jones Named CEO as Aardvark Therapeutics Launches Ardia Subsidiary

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AARD/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":5.09,"timestamp":1773432000000,"preClose":5.26,"halted":0,"volume":266130,"hourTrading":{"tag":"盘后","latestPrice":5.1,"preClose":5.09,"latestTime":"19:24 EDT","volume":1369,"amount":6975.71,"timestamp":1773444250276,"change":0.01,"changeRate":0.001965,"amplitude":0.001965},"delay":0,"changeRate":-0.03231939163498097,"floatShares":5888000,"shares":21696893,"eps":-2.243,"marketStatus":"Market Closed","change":-0.17,"latestTime":"03-13 16:00:00 EDT","open":5.3,"high":5.365,"low":4.83,"amount":1347976.1275199999,"amplitude":0.101711,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.243,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773648000000},"marketStatusCode":7,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":5.26,"postHourTrading":{"tag":"盘后","latestPrice":5.1,"preClose":5.09,"latestTime":"19:24 EDT","volume":1369,"amount":6975.71,"timestamp":1773444250276,"change":0.01,"changeRate":0.001965,"amplitude":0.001965},"volumeRatio":0.5598080998335082,"impliedVol":1.6909,"impliedVolPercentile":0.9167},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","floatShares":5888000,"roa":"-30.81%","roe":"-48.06%","lyrEps":-0.74,"volumeRatio":0.5598080998335082,"shares":21696893,"dividePrice":0,"high":5.365,"amplitude":0.101711,"preClose":5.26,"low":4.83,"week52Low":4.74,"pbRate":"0.90","week52High":17.94,"institutionHeld":0,"latestPrice":5.09,"eps":-2.243,"divideRate":0,"volume":266130,"delay":0,"ttmEps":-2.243,"open":5.3,"prevYearClose":13.125,"prevWeekClose":5.85,"prevMonthClose":12.49,"prevQuarterClose":13.125,"fiveDayClose":5.85,"twentyDayClose":12.28,"sixtyDayClose":14.47},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AARD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"AARD","fiscalQuarterEnding":"2025/09","expectedEps":-0.82,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2025-08-13","symbol":"AARD","fiscalQuarterEnding":"2025/06","expectedEps":-0.52,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-05-14","symbol":"AARD","fiscalQuarterEnding":"2025/03","expectedEps":-0.7,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2025-03-31","symbol":"AARD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AARD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AARD","date":"2026-03-13","current":-2.269282,"percent":0.992537,"low":-51.17654,"twenty":-10.594371,"median":-7.524231,"eighty":-5.747859,"high":-2.187506,"avg":-10.331041,"sd":8.797843,"marketCap":114527410},"quantilePoints":[{"date":"2025-02-21","current":-51.17654,"twenty":-46.993414,"median":-42.216938,"eighty":-39.920668,"marketCap":368880503},{"date":"2025-02-28","current":-39.75453,"twenty":-42.139802,"median":-40.229211,"eighty":-39.232381,"marketCap":286550651},{"date":"2025-03-07","current":-28.243517,"twenty":-40.603022,"median":-39.176012,"eighty":-36.900511,"marketCap":203579269},{"date":"2025-03-14","current":-31.091602,"twenty":-40.336014,"median":-37.766803,"eighty":-30.723725,"marketCap":224108270},{"date":"2025-03-21","current":-27.23482,"twenty":-39.944402,"median":-34.681377,"eighty":-29.198812,"marketCap":196308580},{"date":"2025-03-28","current":-26.404128,"twenty":-39.576524,"median":-30.913597,"eighty":-27.946841,"marketCap":190320955},{"date":"2025-04-04","current":-9.026143,"twenty":-39.119644,"median":-30.068072,"eighty":-27.341623,"marketCap":185830236},{"date":"2025-04-11","current":-7.397773,"twenty":-38.751766,"median":-29.400552,"eighty":-17.252871,"marketCap":152305358},{"date":"2025-04-17","current":-7.977371,"twenty":-38.300819,"median":-28.45119,"eighty":-8.603741,"marketCap":164238114},{"date":"2025-04-25","current":-8.66235,"twenty":-37.766803,"median":-27.946841,"eighty":-8.371497,"marketCap":178340462},{"date":"2025-05-02","current":-11.939711,"twenty":-36.900511,"median":-27.412825,"eighty":-8.371497,"marketCap":245814773},{"date":"2025-05-09","current":-11.307423,"twenty":-34.865316,"median":-26.68597,"eighty":-8.46634,"marketCap":232797221},{"date":"2025-05-16","current":-7.114571,"twenty":-32.693651,"median":-13.552046,"eighty":-8.46634,"marketCap":197215912},{"date":"2025-05-23","current":-7.834638,"twenty":-31.0204,"median":-11.823792,"eighty":-8.360959,"marketCap":217176159},{"date":"2025-05-30","current":-8.061615,"twenty":-30.818661,"median":-11.433881,"eighty":-8.172533,"marketCap":223467976},{"date":"2025-06-06","current":-9.353039,"twenty":-30.367714,"median":-11.107198,"eighty":-8.178795,"marketCap":259266244},{"date":"2025-06-13","current":-8.656453,"twenty":-30.076972,"median":-10.833207,"eighty":-8.210998,"marketCap":239956875},{"date":"2025-06-20","current":-9.454788,"twenty":-30.053238,"median":-10.188135,"eighty":-8.218152,"marketCap":262086713},{"date":"2025-06-27","current":-10.84796,"twenty":-29.697227,"median":-10.664596,"eighty":-8.356744,"marketCap":300705451},{"date":"2025-07-03","current":-10.894921,"twenty":-29.459887,"median":-10.613156,"eighty":-8.365174,"marketCap":302007206},{"date":"2025-07-11","current":-9.861782,"twenty":-29.308323,"median":-10.597502,"eighty":-8.375712,"marketCap":273368592},{"date":"2025-07-18","current":-9.360866,"twenty":-28.618005,"median":-10.433139,"eighty":-8.40036,"marketCap":259483203},{"date":"2025-07-25","current":-10.542714,"twenty":-28.285052,"median":-10.45662,"eighty":-8.474871,"marketCap":292244042},{"date":"2025-08-01","current":-9.4,"twenty":-28.006176,"median":-10.433139,"eighty":-8.577715,"marketCap":260567999},{"date":"2025-08-08","current":-9.368693,"twenty":-27.946841,"median":-10.061366,"eighty":-8.607418,"marketCap":259700162},{"date":"2025-08-15","current":-6.668132,"twenty":-27.567096,"median":-9.861782,"eighty":-8.474871,"marketCap":244307015},{"date":"2025-08-22","current":-5.762071,"twenty":-27.424692,"median":-9.803081,"eighty":-8.329026,"marketCap":211110768},{"date":"2025-08-29","current":-5.027748,"twenty":-27.270421,"median":-9.525229,"eighty":-8.145134,"marketCap":184206621},{"date":"2025-09-05","current":-5.027748,"twenty":-27.074615,"median":-9.478268,"eighty":-8.014507,"marketCap":184206621},{"date":"2025-09-12","current":-4.61321,"twenty":-26.629602,"median":-9.396086,"eighty":-7.797069,"marketCap":169018796},{"date":"2025-09-19","current":-6.685898,"twenty":-23.929853,"median":-9.368693,"eighty":-7.515801,"marketCap":244957921},{"date":"2025-09-26","current":-7.503129,"twenty":-17.043362,"median":-9.298251,"eighty":-7.308831,"marketCap":274899634},{"date":"2025-10-03","current":-9.102059,"twenty":-12.821851,"median":-9.210333,"eighty":-7.389343,"marketCap":333481245},{"date":"2025-10-10","current":-9.824539,"twenty":-12.161077,"median":-9.298251,"eighty":-7.460987,"marketCap":359951454},{"date":"2025-10-17","current":-7.876213,"twenty":-12.040618,"median":-9.212156,"eighty":-7.503145,"marketCap":288568676},{"date":"2025-10-24","current":-6.425331,"twenty":-11.978881,"median":-9.149542,"eighty":-7.334887,"marketCap":235411289},{"date":"2025-10-31","current":-6.194375,"twenty":-11.800608,"median":-9.102059,"eighty":-7.096882,"marketCap":226949500},{"date":"2025-11-07","current":-5.844979,"twenty":-11.619352,"median":-9.083015,"eighty":-6.739195,"marketCap":214148333},{"date":"2025-11-14","current":-6.453893,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"marketCap":236457733},{"date":"2025-11-21","current":-4.209833,"twenty":-11.386619,"median":-8.807467,"eighty":-6.451943,"marketCap":205321954},{"date":"2025-11-28","current":-4.455369,"twenty":-11.26527,"median":-8.719067,"eighty":-6.366112,"marketCap":217297254},{"date":"2025-12-05","current":-5.535729,"twenty":-11.176245,"median":-8.71121,"eighty":-6.20385,"marketCap":269988572},{"date":"2025-12-12","current":-6.968768,"twenty":-11.12541,"median":-8.663092,"eighty":-6.182531,"marketCap":339880775},{"date":"2025-12-19","current":-6.111623,"twenty":-11.06083,"median":-8.610671,"eighty":-6.174808,"marketCap":298076093},{"date":"2025-12-26","current":-6.366088,"twenty":-10.989171,"median":-8.599121,"eighty":-6.172233,"marketCap":310486858},{"date":"2026-01-02","current":-5.859391,"twenty":-10.980741,"median":-8.405995,"eighty":-6.111623,"marketCap":285774195},{"date":"2026-01-09","current":-6.477696,"twenty":-10.894921,"median":-8.362013,"eighty":-6.093766,"marketCap":315930176},{"date":"2026-01-16","current":-6.852697,"twenty":-10.894921,"median":-8.218152,"eighty":-6.111623,"marketCap":334219725},{"date":"2026-01-23","current":-6.732161,"twenty":-10.894921,"median":-8.171191,"eighty":-6.111623,"marketCap":328340941},{"date":"2026-01-30","current":-5.959837,"twenty":-10.857352,"median":-8.086731,"eighty":-6.108052,"marketCap":290673181},{"date":"2026-02-06","current":-5.040192,"twenty":-10.779084,"median":-8.030062,"eighty":-6.020346,"marketCap":245820240},{"date":"2026-02-13","current":-5.482157,"twenty":-10.700911,"median":-7.926792,"eighty":-5.956266,"marketCap":267375780},{"date":"2026-02-20","current":-5.540193,"twenty":-10.673027,"median":-7.864204,"eighty":-5.92323,"marketCap":270206305},{"date":"2026-02-27","current":-5.580372,"twenty":-10.643124,"median":-7.834638,"eighty":-5.890776,"marketCap":272165900},{"date":"2026-03-06","current":-2.562507,"twenty":-10.619417,"median":-7.684115,"eighty":-5.801764,"marketCap":124978581},{"date":"2026-03-13","current":-2.34822,"twenty":-10.594371,"median":-7.524231,"eighty":-5.747859,"marketCap":114527410}],"updateTime":1773600969739},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AARD\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614898320","title":"Aardvark Therapeutics Pauses Trial After Finding Safety Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2614898320","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614898320?lang=en_us&edition=fundamental","pubTime":"2026-02-28 06:20","pubTimestamp":1772230800,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics is voluntarily pausing a Phase 3 trial of a drug to treat hyperphagia in patients with Prader-Willi Syndrome.The biopharmaceutical company said it is pausing the trial after finding reversible cardiac observations at above target therapeutic doses in a healthy volunteer study.The company no longer anticipates announcing topline data from the trial with a hunger elimination or reduction objective in the third quarter of 2026, it said. It plans to provide further guidance in the second quarter of this year.Shares tumbled 57%, to $5.45, in after-hours trading Friday. Through the close, the stock was up 25% over the past three months.The trial is for ARD-101, which has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies. The FDA has granted ARD-101 orphan drug designation and rare pediatric disease designation for Prader-Willi Syndrome.Prader-Willi is a rare genetic disorder which can result in hyperphagi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2614260860","title":"BUZZ-Aardvark Therapeutics falls after pausing late-stage rare disease trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2614260860","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614260860?lang=en_us&edition=fundamental","pubTime":"2026-02-28 06:13","pubTimestamp":1772230382,"startTime":"0","endTime":"0","summary":"BUZZ-Aardvark Therapeutics falls after pausing late-stage rare disease trial ** Shares of drug developer Aardvark Therapeutics AARD.O fall 47.2% to $6.58 aftermarkets ** Co says it is voluntarily pausing its late-stage trial testing its experimental treatment for a type of rare genetic disease** Says decision was made after it found heart-related side effects during safety monitoring in a healthy volunteer study in patients receiving higherthanplanned doses of the treatment     ** Says no longer anticipates announcing topline data from the trial in the third quarter of 2026** Stock has fallen 12.6% since its Nasdaq debut last year   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL4N3ZN24O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2614898854","title":"Aardvark Therapeutics down 54% to $5.70 after pausing Phase 3 HERO trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2614898854","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614898854?lang=en_us&edition=fundamental","pubTime":"2026-02-28 06:00","pubTimestamp":1772229647,"startTime":"0","endTime":"0","summary":"16:57 EST Aardvark Therapeutics (AARD) down 54% to $5.70 after pausing Phase 3 HERO trial Published first on TheFly – the ultimate source for real-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-down-54-to-5-70-after-pausing-phase-3-hero-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-down-54-to-5-70-after-pausing-phase-3-hero-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD","HERO"],"gpt_icon":0},{"id":"2614095862","title":"Aardvark Therapeutics voluntarily pauses Phase 3 HERO trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2614095862","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614095862?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:11","pubTimestamp":1772226663,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (AARD) announced it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective trial. The HERO trial is a P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-voluntarily-pauses-phase-3-hero-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-voluntarily-pauses-phase-3-hero-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD","HERO"],"gpt_icon":0},{"id":"2614862431","title":"Aardvark Therapeutics pauses late-stage trial testing rare disease treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2614862431","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614862431?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:10","pubTimestamp":1772226648,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics pauses late-stage trial testing rare disease treatment Feb 27  - Aardvark Therapeutics AARD.O on Friday said it is voluntarily pausing its late-stage trial testing its experimental treatment for a type of rare genetic disease.   ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL4N3ZN20N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2614862160","title":"Aardvark Therapeutics: Decision Based on Reversible Cardiac Observations at Above Target Therapeutic Doses Found","url":"https://stock-news.laohu8.com/highlight/detail?id=2614862160","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614862160?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:07","pubTimestamp":1772226431,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nPLXF641A3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2614198862","title":"Aardvark Therapeutics: Hero & Open-Label Open-Label Extension Trials Pause Based on Reversible Cardiac Observations Above Target Doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2614198862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614198862?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:07","pubTimestamp":1772226431,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nPLXF641A3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2614862131","title":"Aardvark Therapeutics pauses Phase 3 HERO trial of ARD-101 in Prader-Willi syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2614862131","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614862131?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:05","pubTimestamp":1772226337,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics said it is voluntarily pausing enrollment and dosing in its Phase 3 HERO trial evaluating ARD-101 for hyperphagia in patients with Prader-Willi syndrome, along with the related open-label extension study. The pause follows reversible cardiac observations at above-target therapeutic doses identified during routine safety monitoring in a healthy volunteer study, and the company is conducting a comprehensive data review while continuing discussions with the FDA and experts. Aardvark said it no longer expects to report HERO topline data in the third quarter of 2026 and plans to provide further guidance in the second quarter of 2026; no trial efficacy results were reported in the announcement.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL6FLBcG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014021.USD","BK4112","IE00B64PRP62.GBP","AARD","LU2095319765.USD","SG9999014013.SGD","LU2210150020.SGD","BK4588","NDAQ","SG9999014005.SGD","LU0314104364.USD","SG9999014039.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2614686209","title":"Aardvark Therapeutics Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2614686209","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614686209?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:05","pubTimestamp":1772226320,"startTime":"0","endTime":"0","summary":"16:02 EST Aardvark Therapeutics (AARD) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-movin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2614967862","title":"Aardvark Therapeutics Announces Voluntary Pause of Phase 3 Hero Trial in Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2614967862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614967862?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:05","pubTimestamp":1772226300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nTUA34LWS9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2614786216","title":"Aardvark Therapeutics Inc - Pause Due to Cardiac Observations at Above Target Doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2614786216","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614786216?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:05","pubTimestamp":1772226300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nTUA34LWS9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2614286219","title":"Aardvark Therapeutics Inc - Topline Data Announcement Delayed, Guidance Expected in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614286219","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614286219?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:05","pubTimestamp":1772226300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nTUA34LWS9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2614862954","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 04:02 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2614862954","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614862954?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:02","pubTimestamp":1772226126,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 04:02 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nAQN2LO3MU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2611150917","title":"BRIEF-Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611150917","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611150917?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:46","pubTimestamp":1770990387,"startTime":"0","endTime":"0","summary":"BRIEF-Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Feb 13 (Reuters) - Aardvark Therapeutics Inc AARD.O:AARDVARK THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nTUA2TNZP4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2611521771","title":"Aardvark Therapeutics Grants Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2611521771","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611521771?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:00","pubTimestamp":1770987614,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. has granted inducement stock options to six new employees under its 2025 Inducement Equity Incentive Plan. On February 9, 2026, five employees received options to purchase a total of 147,213 shares at an exercise price of $13.48 per share, and on February 11, 2026, one employee received an option for 5,125 shares at an exercise price of $12.67 per share. Each option vests over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 13, 2026, and is solely","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL3Yy8LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014021.USD","IE00BKPKM429.USD","BK4588","SG9999014013.SGD","AARD","LU0314104364.USD","BK4112","LU2210150020.SGD","SG9999014005.SGD","LU2210149790.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","BK4585","NDAQ"],"gpt_icon":0},{"id":"2610987927","title":"BRIEF-Aardvark Therapeutics Announces Establishment Of New U.S. Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2610987927","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610987927?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:40","pubTimestamp":1770907208,"startTime":"0","endTime":"0","summary":"BRIEF-Aardvark Therapeutics Announces Establishment Of New U.S. Subsidiary Feb 12 (Reuters) - Aardvark Therapeutics Inc AARD.O:AARDVARK THERAPEUTICS ANNOUNCES ESTABLISHMENT OF NEW U.S. SUBSIDIARY TO S","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA4MZRKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2610492992","title":"Aardvark Therapeutics Launches Ardia Subsidiary for Dermatology Pipeline Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2610492992","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610492992?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:06","pubTimestamp":1770901615,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the establishment of Ardia Therapeutics, Inc., a new wholly-owned U.S. subsidiary aimed at supporting the development of its dermatology pipeline. Ardia will focus on advancing DIA-615, a potential topical treatment for inflammatory skin diseases such as psoriasis. Bryan Jones, Ph.D., previously Aardvark's Chief Operating Officer, has been appointed Chief Executive Officer of Ardia to lead this new initiative.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL9jMZ57:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2610092958","title":"Aardvark Therapeutics Appoints Derrick C. Li as Chief Business Officer and Expands Nelson Sun's Role","url":"https://stock-news.laohu8.com/highlight/detail?id=2610092958","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610092958?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:01","pubTimestamp":1770901289,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. has appointed Derrick C. Li as Chief Business Officer and expanded Nelson Sun’s role to include Chief Operating Officer in addition to his current position as Chief Financial Officer. These changes are effective as of February 9, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL92vgJm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","AARD","LU2210150020.SGD","BK4588","BK4112","LU2210149790.SGD","SG9999014005.SGD","SG9999014039.USD","BK4585","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014013.SGD"],"gpt_icon":0},{"id":"2610929318","title":"Bryan Jones Named CEO as Aardvark Therapeutics Launches Ardia Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2610929318","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610929318?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901225,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. has established a new U.S. subsidiary, Ardia Therapeutics, Inc., to support its dermatology pipeline. Bryan Jones, Ph.D., formerly Chief Operating Officer of Aardvark, has been appointed Chief Executive Officer of Ardia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDLcf6Yb5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","AARD","LU2210150020.SGD","BK4588","BK4112","LU2210149790.SGD","SG9999014005.SGD","SG9999014039.USD","BK4585","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014013.SGD"],"gpt_icon":0},{"id":"2610929828","title":"Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2610929828","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610929828?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA4MZRKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":98,"code":"91000000","status":"200"}]}}